Coronavirus (COVID-19 ou SARS-COV-2): clinical trials assessment
Clinical tests (TRL5 to TRL9) of the new corona virus have been mapped in order to obtain the current state of the art. The international base of the World Health Organization was mapped and complemented with national bases. After screening, 661 documents remained and were analyzed. There are studie...
| Authors: | , , , , |
|---|---|
| Format: | article |
| Status: | Published version |
| Publication Date: | 2020 |
| Country: | Brasil |
| Institution: | Universidade Federal da Bahia (UFBA) |
| Repository: | Cadernos de Prospecção (Online) |
| Language: | Portuguese |
| OAI Identifier: | oai:ojs.periodicos.ufba.br:article/36175 |
| Online Access: | https://periodicos.ufba.br/index.php/nit/article/view/36175 |
| Access Level: | Open access |
| Keyword: | Terapias Avaliação Tecnológica Níveis de Maturidade Tecnológica TRL. Pandemics Therapies Technology Assessment Technology Readiness Levels |
| Summary: | Clinical tests (TRL5 to TRL9) of the new corona virus have been mapped in order to obtain the current state of the art. The international base of the World Health Organization was mapped and complemented with national bases. After screening, 661 documents remained and were analyzed. There are studies in 25 countries, although they are concentrated in China. Companies finance less than 6% of studies. The vast majority of studies are in Phase Zero (preclinical), only 2% are already in progress and none has results yet. Their primary goals are therapeutics; however, a large majority are dedicated to Chinese medicine and only 245 are focusing on antiviral, immunotherapy and vaccine transnational technologies. There is a wide range of active compounds, mainly referring to hydroxychloroquine/chloroquine (31) and stem cells (22). The age groups of the patients focus especially on adolescents and adults and leave long-lived patients uncovered. |
|---|